Cell Signaling Technology

Product Pathways - Translational Control

FXR1 (L662) Antibody #4264

Applications Reactivity Sensitivity MW (kDa) Source
W M Endogenous 78-80, 82-84 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  M=Mouse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

FXR1 (L662) Antibody detects endogenous levels of total FXR1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence of mouse FXR1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from C2C12 cells using FXR1 (L662) Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from mouse skeletal muscle using FXR1 (L662) Antibody.

Background

Fragile X syndrome is a genetic disorder characterized by a spectrum of physical and behavioral features and is a frequent form of inherited mental retardation (1). X-linked FMRP (FMR-1) and its two autosomal homologs, FXR1 and FXR2, are polyribosome-associated RNA-binding proteins that are involved in the pathogenesis of fragile X syndrome (1-3). Each of the fragile X proteins can self-associate, as well as form heteromers with the other two related proteins (3). FMRP can act as a translation regulator and is a component of RNAi effector complexes (RISC), suggesting a role in gene silencing (4). The Drosophila homolog of FMRP (dFMRP) associates with Argonaute 2 (Ago2) and Dicer and can coimmunoprecipitate with miRNA and siRNA (5). These results suggest that fragile X syndrome is related to abnormal translation caused by defects in RNAi-related pathways. In addition, FMRP, FXR1, and FXR2 are components of stress granules (SG) and have been implicated in the translational regulation of mRNAs (6).

  1. Verkerk, A.J. et al. (1991) Cell 65, 905-14.
  2. Siomi, M.C. et al. (1995) EMBO J 14, 2401-8.
  3. Zhang, Y. et al. (1995) EMBO J 14, 5358-66.
  4. Caudy, A.A. et al. (2002) Genes Dev 16, 2491-6.
  5. Siomi, H. et al. (2004) Ment Retard Dev Disabil Res Rev 10, 68-74.
  6. Linder, B. et al. (2008) Hum Mol Genet 17, 3236-46.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products